BTAI
BioXcel Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.07
+0.00%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$1.01
- Revenue estimate
- $191.4K
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.49
- EPS estimate
- -$0.51
- Revenue actual
- $182.0K
- Revenue estimate
- $169.3K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -6.7%
- Revenue beats (12Q)
- 4
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.51 | -$0.49 | Beat 3.92% | $182.0K |
| May 15, 2026 | -$0.59 | -$0.54 | Beat 8.47% | $206.0K |
| Mar 27, 2026 | -$0.59 | -$0.58 | Beat 2.25% | $256.0K |
| Nov 12, 2025 | -$1.54 | -$2.18 | Miss -41.56% | $98.0K |
| Aug 12, 2025 | -$2.30 | -$2.45 | Miss -6.52% | $120.0K |
| Mar 27, 2025 | -$4.36 | -$3.57 | Beat 18.12% | $366.0K |
| Nov 14, 2024 | -$8.00 | -$5.12 | Beat 36.00% | $214.0K |
| May 9, 2024 | -$11 | -$14 | Miss -27.94% | $582.0K |
| Mar 12, 2024 | -$16 | -$12 | Beat 22.45% | $376.0K |
| Nov 14, 2023 | -$21 | -$28 | Miss -33.33% | $341.0K |
| Aug 14, 2023 | -$28 | -$29 | Miss -6.40% | $457.0K |
| Mar 9, 2023 | -$24 | -$31 | Miss -30.87% | $238.0K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026